v3.26.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Income Tax Disclosure [Abstract]    
Net operating loss carry-forward $ 5,108,580 $ 4,555,400
Section 174 Qualified Research Expenditures 1,729,805 1,232,033
Stock compensation 2,696,830 1,099,090
R&D Credit 54,092 38,640
Other
Deferred tax assets, Gross 9,589,307 6,925,163
Less: valuation allowance (9,589,307) (6,925,163)
Total net deferred tax asset